Novartis Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Novartis Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#16 of 15,742 sponsors by registered trial count).
Novartis Pharmaceuticals: 1,375 sponsored US clinical trials, 110 recruiting.
Novartis Pharmaceuticals sponsors 1,375 registered US clinical trials on ClinicalTrials.gov, 110 of them currently recruiting, and 944 completed. 470 of these trials are in Phase 3-4 (later-stage) and 776 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Small Cell Lung Cancer, with 10 trials.
Top-decile sponsor footprint
Novartis Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#16 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
944 of 1,179 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,375 total, page 16 of 28
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
NCT01844765
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
NCT01920477
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation
NCT01744665
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
NCT01831726
Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)
NCT01757691
To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension
NCT02047656
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)
NCT01822613
A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function
NCT01904214
Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus
NCT01915849
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
NCT01828112
Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator
NCT01802879
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
NCT01807520
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis
NCT01806597
Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer
NCT01772797
Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients
NCT01811472
Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis
NCT01828086
Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma
NCT01747876
A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects
NCT01677741
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
NCT01789281
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)
NCT01708174
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
NCT01836471
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.
NCT01700270
Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia
NCT01826214
Study of Safety of Foradil in Patients With Persistent Asthma
NCT01845025
Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia
NCT01566630
A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures
NCT01713946
Efficacy and Tolerability of BAF312 in Patients With Polymyositis
NCT01801917
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
NCT01752634
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients
NCT01769768
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
NCT01735955
BKM120 for Patients With PI3K-activated Tumors
NCT01833169
A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors
NCT01760525
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
NCT01784068
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer
NCT01698918
An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction
NCT01846468
Effect of Hepatic Impairment on LDE225..
NCT01764776
Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients
NCT01825980
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
NCT01693614
A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients
NCT01735968
A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.
NCT01783444
Ext. Long-term Safety Study in CF Patients: Single Arm TIP
NCT01775137
Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.
NCT01589237
Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome
NCT01637272
Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).
NCT01682083
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients
NCT02089087
Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
NCT01691807
Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment
NCT01688882
Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
NCT01625182
Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,
NCT01526889
Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
NCT01698905
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 326 |
| Phase 2 | 450 |
| Phase 3 | 393 |
| Phase 4 | 77 |
What is open in the Novartis Pharmaceuticals pipeline
110 recruiting of 1,375 indexed (8% open); 944 completed (69%).
Phase mix: 470 late (III/IV) vs 776 early (I/II) (early-phase heavy).
Top condition: Non-Small Cell Lung Cancer (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Novartis Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 1,375 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Novartis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,375 trials (± recruiting share)
- GlaxoSmithKline · 1,345 trials · 4% recruiting
- Eli Lilly and Company · 1,341 trials · 9% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Arcutis Biotherapeutics · 8% recruiting · 25 trials
- Medtronic Endovascular · 8% recruiting · 25 trials
- Penumbra · 8% recruiting · 25 trials
- SK Life Science · 8% recruiting · 25 trials
Related
What to do with this Novartis Pharmaceuticals page
1,375 registered trials is a research-attention snapshot, not an endorsement of Novartis Pharmaceuticals or any single study.
- 110 of Novartis Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Non-Small Cell Lung Cancer is the condition Novartis Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Small Cell Lung Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Novartis Pharmaceuticals pipeline card: 1,375 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.